OBJECTIVES: Health plans monitor daily dosing of pharmaceuticals by calculating daily average consumption (DACON) and average daily cost ($ADC) on the basis of aggregate pharmacy data We examined DACON and $ADC for duloxetine-treated patients with 1 or more disorders for which duloxetine has received FDA approval. METHODS: This retrospective analysis examined US commercially insured patients who received ≥1 prescription of duloxetine during 2008 for 1 or more of the following disorders: major depressive disorder (MDD), diabetic peripheral neuropathic pain (DPNP), generalized anxiety disorder (GAD), or fibromyalgia (FM). Patients were assigned to subgroups by indication based on diagnosis codes recorded during the 12 months prior to their first recorded duloxetine prescription during the study interval. DACON was calculated by dividing total pills dispensed by total days of supply. $ADCs were calculated using June 2009 new wholesale prices. RESULTS: There were 47,089 duloxetine-treated patients from 2008 included in the analysis, 28,313 with diagnosed MDD, 16,285 with FM, 5,769 with GAD, and 2,575 with DPNP. Overall DACON for duloxetine among all patients was 1.34 capsules per day, and $ADC was $5.44. For duloxetine-treated patients with MDD only (no GAD, DPNP, or FM), DACON and $ADC were 1.42 and $5.62, respectively. For patients with FM only, DACON/$ADC were 1.28/$5.10; for GAD only, 1.25/$4.96; and for DPNP only, 1.25/$4.99. DACON and $ADC were higher among patients with both MDD and another indicated disorder: 1.52/$6.06 for MDD and FM; 1.47/$5.85 for MDD and GAD, and 1.50/$5.98 for MDD and DPNP. CONCLUSIONS: DACON and $ADC for duloxetine were higher for patients with MDD alone than for patients with GAD, DPNP, or FM alone. DACON and $ADC were somewhat higher for patients with MDD and another indicated disorder than for MDD alone, though there was little variation in these measures with respect to which indication MDD was paired.